Brainstorm Cell Therapeutics Inc.

Greetings and welcome to the Brainstorm Cell Therapeutics first quarter 2022 conference call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded. And I would now like to introduce your host for today's conference, Tom Galassi of LifeSci Advisors. Mr. Galassi, you may begin.

Good morning and thank you for joining us. Before we begin the opening remarks, We would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding brainstormed cell therapeutics and its potential future operations and performance. Statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness for the Neuron technology platform, clinical trials of Neuron, and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time to time in its SEC filings. The company's results may differ materially from those projected on today's call. The company undertakes no obligation to publicly update any forward-looking statements. Joining me on the call today will be Hyman Leibovitz, CEO of Brainstorm, Anala Patlis, Interim Chief Financial Officer. In addition, Dr. Stacey Lindberg, Executive Vice President and Chief Development Officer, Dr. Ralph Kern, President and Chief Medical Officer, and Dr. David Sepin, Executive Vice President and Chief Operating Officer, are also on the call and will be available to answer your questions during the Q&A session. Now, I'd like to turn the call over to Mr. Leibovitz. Please go ahead.

Thanks, Tom.